What’s next for VEGF? ASCO offered clues, but answers will have to wait

Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses.

Raccontata daendpoints.news